Physician

William Smith, MD

Study Coordinator

Amy Grossman RN
484-658-1788
Amy.Grossman@sluhn.org

Close

Synopsis: This study will evaluate real-world clinical outcomes and patient reported outcomes that measure the effecitveness and safety of GammaTiles™ (GT).

Close

• Patients must be scheduled to undergo maximum safe resection of intracranial neoplasm(s) AND implantation of GammaTiles
• Patients must be able to undergo pre- and post-operative imaging for disease implant assessment
• Patients must be fluent in either English or Spanish to allow for informed consent and completion of Quality of Life tests

Close

Physician

David Andolino, MD

Study Coordinator

Amy Grossman RN
email: 484-658-1788
phone: Amy.Grossman@sluhn.org

Close

This study is being done to help determine if a type of SRS radiation treatment called fractionated SRS (or FSRS) completed over 3 treatments to the areas of cancer in your brain can delay the time until the cancer worsens or returns compared to the usual SRS given in 1 treatment.

Close

Your doctor will determine whether this clinical trial is an appropriate option for you. Some key eligibility criteria are as follows:

• Participants must have a proven diagnosis of one of the following solid tumor malignancies within 5 years of study enrollment:
  • Non-small cell lung cancer
  • Melanoma
  • Breast cancer
  • Renal cell cancer
  • Gastrointestinal cancer
• Participants must have at least 1 and up to 8 total intact brain metastases detected on an MRI within 21 days of study enrollment
• The brain lesions must by ≥ 1 cm and ≤ 3 cm in size
• All brain metastases must be located outside of the brainstem and ≥ 5 mm from the optic nerve or optic chiasm and ≤ 3 cm in maximum dimension
• Participants must be ≥ 18 years of age
• No prior radiotherapy to the brain
• No more than 2 lesions planned for resection if clinically indicate
• Karnofsky performance score of ≥ 60

Close